NEW-18019062-New-starter-Gordon-Muir-2023-850x846-1.jpg

Gordon Muir-Jones Joins the Prime Team

People are at the heart of everything we do, and Prime people make our business uniquely successful.

We are thrilled to announce the arrival of Gordon Muir-Jones to our team. Gordon is both highly regarded and experienced, having been directly involved in the development and implementation of multiple global and domestic medical communications projects for over 30 years.

read more >>
Prime GlobalGordon Muir-Jones Joins the Prime Team
18019062-Aventine-web-update.png

Prime welcomes Aventine Consulting to our team

We are thrilled to announce the acquisition of Aventine Consulting LLC.

Aventine Consulting LLC, founded by Holly Trautman and Jamie Dunning in 2008, is a US-based consulting firm specialising in US-focused market access and payer communications.

Joining forces with Aventine will enable Prime to offer a full spectrum of health economics, market access, value communications and evidence services. Importantly, providing a local US presence to geographically support US-based global clients and meet the increasing needs of the US domestic market.

read more >>
Prime GlobalPrime welcomes Aventine Consulting to our team
shutterstock_1323802778_2500.jpg

Breast cancer treatment: decision-making through a health literacy lens

In recognition of both Health Literacy Month and Breast Cancer Awareness Month, we’re looking at the unmet treatment education needs of people living with breast cancer who experience low health literacy.

read more >>
Prime GlobalBreast cancer treatment: decision-making through a health literacy lens
shutterstock_1070449649_2500.jpg

Patient-reported outcomes in metastatic breast cancer: delivering multistakeholder value through patient centricity

October is World Breast Cancer Awareness Month, and 13 October is Metastatic Breast Cancer Awareness Day. Let’s look at how the views of people living with metastatic breast cancer provide a vital, underestimated component of assessing the benefits of novel treatments. 

read more >>
Prime GlobalPatient-reported outcomes in metastatic breast cancer: delivering multistakeholder value through patient centricity
Prime-Global-Welcomes-Earthware-v2.jpg

Prime Global acquires award-winning digital agency earthware, enhancing digital and technology expertise

Prime Global, a recognised global leader in medical communications, evidence and access, and patient engagement, has acquired earthware, an award-winning creative digital agency that creates life-changing solutions to real world healthcare problems. earthware joins Prime Global in supporting pharma and biotech clients at every step of the healthcare journey; their industry-leading technology expertise will complement Prime Global’s scientific heritage and proven delivery, enhancing and expanding Prime Global’s existing digital capabilities.

read more >>
Prime GlobalPrime Global acquires award-winning digital agency earthware, enhancing digital and technology expertise
pexels-tristan-le-1642883-scaled.jpg

Dementia and patient engagement: not as incompatible as you might think

An estimated 57.4 million people live with dementia worldwide, (1) and unfortunately, clinical trials for dementia treatments have resulted in few pharmacotherapies – none of them curative. (2) (3) (4) For World Alzheimer’s Day, Prime Patient explore how Pharma can collaborate with people living with dementia to optimise the industry’s dementia research and patient community support.

read more >>
Prime GlobalDementia and patient engagement: not as incompatible as you might think
Disability-inclusion-re-size-for-web.jpg

Disability inclusion in clinical trials and equity in outcomes

Many agree that disability inclusion in clinical trials is a worthy pursuit, but the historical significance and future impact of pursuing this goal is relatively unexplored. Here, we peel back the layers of this vital mission.

read more >>
Prime GlobalDisability inclusion in clinical trials and equity in outcomes
Patient-Centricity-Engagement-conference.png

Not just a buzzword: how Pharma and advocacy leaders are effecting meaningful patient centricity

On May 24th, the Prime Patient team was fortunate to have a spot at 2022’s Patient Centricity and Engagement Conference, hosted in London, England. With a veritable smorgasbord of topics up for discussion, we were spoiled for choice! Here we summarise some highlights from the day, kicking off with tips on strengthening patient advocacy collaboration. 

read more >>
Prime GlobalNot just a buzzword: how Pharma and advocacy leaders are effecting meaningful patient centricity
WHD2022-1200x350-EN-1.jpg

Haemophilia awareness: building trusted relationships between patients and industry

Haemophilia is a lifelong genetic disorder characterised by excessive bleeding.(1) Despite the existence of treatments for haemophilia, the condition continues to have major impacts on quality of life, for example in the areas of pain (acute and chronic), joint mobility, and physical function.(1) To mark World Haemophilia Day on 17 April, Prime Patient partnered with sister agency HCD Economics, a consultancy specialising in haemophilia patient research, and haemophilia advocate Laurence Woollard to better understand the existing relationship between patients and industry and how meaningful improvements can be made to the lives of people living with haemophilia (PwH).

read more >>
Prime GlobalHaemophilia awareness: building trusted relationships between patients and industry
shutterstock_1074052664_2500-1.jpg

Patient engagement in rare mutation cancers

Patient advocacy and engagement are important no matter the disease area, whether it’s a common condition or one that few have heard of. Following the recent celebration of Rare Disease Day, let’s take a closer look at patient engagement in rare mutation cancers. 

read more >>
Prime GlobalPatient engagement in rare mutation cancers
18010354_Rare-disease-day_posts_v3_1.png

Amplifying the Patient Voice in Rare Diseases

Medical publishing is evolving beyond plain language summaries to provide insightful, patient-centred resources to change the course of pharmaceutical research for the better. For patients with rare diseases especially, this could be just what the doctor ordered, writes Olivia Kersey, Patient Engagement Strategist with Prime Patient.

read more >>
Prime GlobalAmplifying the Patient Voice in Rare Diseases
Support-Pledge-Strapline-1920x1080_ENGLISH.png

Rare reflections: has the pandemic helped or hindered patient engagement and research for rare diseases?

Emma Sutcliffe, SVP Patient Insights and Solutions, Prime Patient shares her reflections about whether the pandemic has helped or hindered patient engagement and research for rare diseases.

read more >>
Prime GlobalRare reflections: has the pandemic helped or hindered patient engagement and research for rare diseases?
18010354_WHO_post_illustrations_v5-02.png

How to make 2022 the best year yet for patient engagement

Olivia Kersey, Patient Engagement Strategist, outlines what we can learn from 2021 to optimise patient engagement strategy and implementation in 2022.

While there would be no such thing as the pharmaceutical industry without patients, it’s only in recent years that collaboration with patients has started to enter the mainstream. While 2021 was a good year for patient engagement, 2022 can be both bigger and better.

read more >>
Prime GlobalHow to make 2022 the best year yet for patient engagement